search
Back to results

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)

Primary Purpose

Appendicitis, Cholecystitis, Diverticulitis

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
tigecycline
ceftriaxone plus metronidazole
Sponsored by
Wyeth is now a wholly owned subsidiary of Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Appendicitis focused on measuring Intra-Abdominal Infections, Abscess

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours. Fever plus other symptoms such as nausea, vomiting, abdominal pain. Exclusion Criteria: Cancer Medicines that suppress the immune system Dialysis

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

A

B

Arm Description

Outcomes

Primary Outcome Measures

Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit
CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. Clinical response was assigned by investigator per protocol-specified guidelines and defined as: test article and initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. TOC performed 10-28 days after last dose of study drug.

Secondary Outcome Measures

Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit
ME population were subjects who were clinically evaluable and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit
Microbiological response was assessed at patient level was the combined responses for all baseline isolates identified in intra-abdominal and blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=No sample for culture, clinical response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=No sample available for culture, clinical response was failure; Superinfection=culture from primary infection site with new isolate not identified at baseline, clinical response was failure.
Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure
Healthcare resource utilization assessment included days of overall inpatient hospitalization, days of primary inpatient hospitalization, days of Intensive Care Unit (ICU) treatment and days of non-ICU inpatient hospitalization

Full Information

First Posted
September 30, 2005
Last Updated
February 20, 2013
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00230971
Brief Title
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Official Title
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

4. Oversight

5. Study Description

Brief Summary
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess, Intra-Abdominal Infection, Peritonitis
Keywords
Intra-Abdominal Infections, Abscess

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
473 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Title
B
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
tigecycline
Intervention Description
every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Intervention Type
Drug
Intervention Name(s)
ceftriaxone plus metronidazole
Intervention Description
Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Primary Outcome Measure Information:
Title
Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit
Description
CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. Clinical response was assigned by investigator per protocol-specified guidelines and defined as: test article and initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. TOC performed 10-28 days after last dose of study drug.
Time Frame
up to 6 weeks
Secondary Outcome Measure Information:
Title
Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit
Description
ME population were subjects who were clinically evaluable and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.
Time Frame
up to 6 weeks
Title
Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit
Description
Microbiological response was assessed at patient level was the combined responses for all baseline isolates identified in intra-abdominal and blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=No sample for culture, clinical response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=No sample available for culture, clinical response was failure; Superinfection=culture from primary infection site with new isolate not identified at baseline, clinical response was failure.
Time Frame
up to 6 weeks
Title
Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure
Description
Healthcare resource utilization assessment included days of overall inpatient hospitalization, days of primary inpatient hospitalization, days of Intensive Care Unit (ICU) treatment and days of non-ICU inpatient hospitalization
Time Frame
up to 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours. Fever plus other symptoms such as nausea, vomiting, abdominal pain. Exclusion Criteria: Cancer Medicines that suppress the immune system Dialysis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Wyeth is now a wholly owned subsidiary of Pfizer
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Australia, China, Hong Kong, medinfo@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Taiwan, medinfo@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Denmark, Finland, MedInfoNord@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Germany, MedinfoDEU@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For South Africa, ZAFinfo@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Italy, Greece, decresg@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For UK, ukmedinfo@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Switzerland, med@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For France, infomedfrance@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Spain, infomed@wyeth.com
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Trial Manager
Organizational Affiliation
For Turkey, Erisc@wyeth.com
Official's Role
Principal Investigator
Facility Information:
City
Nambour
State/Province
Queensland
ZIP/Postal Code
4560
Country
Australia
City
Cairns
ZIP/Postal Code
QLD 4870
Country
Australia
City
Parkville
ZIP/Postal Code
VIC 3050
Country
Australia
City
Shanghai
ZIP/Postal Code
200032
Country
China
City
Odense
ZIP/Postal Code
5000
Country
Denmark
City
Lahti
ZIP/Postal Code
15850
Country
Finland
City
Seinajoki
ZIP/Postal Code
60220
Country
Finland
City
Tampere
ZIP/Postal Code
33101
Country
Finland
City
Marseille
ZIP/Postal Code
13 009
Country
France
City
Nimes
ZIP/Postal Code
30 029
Country
France
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
City
Saint Denis
ZIP/Postal Code
93205
Country
France
City
Bochum
ZIP/Postal Code
44791
Country
Germany
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
City
Leipzig
ZIP/Postal Code
04129
Country
Germany
City
Luebeck
ZIP/Postal Code
23538
Country
Germany
City
Muenster
ZIP/Postal Code
48149
Country
Germany
City
Tuebingen
ZIP/Postal Code
72056
Country
Germany
City
Athens
ZIP/Postal Code
11527
Country
Greece
City
Athens
ZIP/Postal Code
12462
Country
Greece
City
Thessaloniki
ZIP/Postal Code
54623
Country
Greece
City
New Territories
Country
Hong Kong
City
Pokfulam
Country
Hong Kong
City
Hyderabad
State/Province
Andhra
ZIP/Postal Code
500 082
Country
India
City
Bhopal
ZIP/Postal Code
462 038
Country
India
City
Lucknow
ZIP/Postal Code
226 014
Country
India
City
Mumbai
ZIP/Postal Code
400071
Country
India
City
New Delhi
ZIP/Postal Code
110060
Country
India
City
Brescia
ZIP/Postal Code
25123
Country
Italy
City
Genova
ZIP/Postal Code
16132
Country
Italy
City
Pavia
ZIP/Postal Code
27100
Country
Italy
City
Rome
ZIP/Postal Code
00168
Country
Italy
City
Udine
ZIP/Postal Code
33100
Country
Italy
City
Vicenza
ZIP/Postal Code
36100
Country
Italy
City
Manila
ZIP/Postal Code
1000
Country
Philippines
City
Quezon City
ZIP/Postal Code
1100
Country
Philippines
City
Quezon City
ZIP/Postal Code
1105
Country
Philippines
City
Almada
ZIP/Postal Code
2801-951
Country
Portugal
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
City
Porto
ZIP/Postal Code
4099-100
Country
Portugal
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
City
Riyadh
Country
Saudi Arabia
City
Bellville
ZIP/Postal Code
7530
Country
South Africa
City
Kuilsriver
ZIP/Postal Code
7580
Country
South Africa
City
Parow
ZIP/Postal Code
7505
Country
South Africa
City
Pietermaritzburg
ZIP/Postal Code
3201
Country
South Africa
City
Pretoria
ZIP/Postal Code
001
Country
South Africa
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
City
Bilbao
ZIP/Postal Code
48903
Country
Spain
City
Madrid
ZIP/Postal Code
28040
Country
Spain
City
Madrid
ZIP/Postal Code
28905
Country
Spain
City
Murcia
ZIP/Postal Code
30120
Country
Spain
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
City
Geneva
ZIP/Postal Code
1211
Country
Switzerland
City
Lugano
ZIP/Postal Code
6900
Country
Switzerland
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
City
Changhua
ZIP/Postal Code
500
Country
Taiwan
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
City
Tainan
Country
Taiwan
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
City
Tao-yuan
ZIP/Postal Code
333
Country
Taiwan
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
City
Istanbul
ZIP/Postal Code
34718
Country
Turkey
City
Stockport
State/Province
Cheshire
ZIP/Postal Code
SK2 7JE
Country
United Kingdom
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
City
Wigan
ZIP/Postal Code
WN1 2NN
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
22439781
Citation
Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt). 2012 Apr;13(2):102-9. doi: 10.1089/sur.2011.048. Epub 2012 Mar 22.
Results Reference
derived

Learn more about this trial

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)

We'll reach out to this number within 24 hrs